文献速递免疫规划

克氏锥虫抗原蛋白表位定位构建亚单位疫苗的免疫信息学研究

Examination of antigenic proteins of Trypanosoma cruzi to fabricate an epitope-based subunit vaccine by exploiting epitope mapping mechanism.
PubMed 文献 · Vaccine · 2018-09-11

本研究采用免疫信息学方法设计针对克氏锥虫感染的多表位亚单位疫苗,基于B细胞和T细胞表位评估免疫原性,预测变应原性和抗原性以确保安全性,理化性质显示疫苗模型稳定。分子对接和分子动力学模拟确认疫苗模型与TLR-2和TLR-4受体复合物的稳定性。该研究需要实验验证所设计疫苗蛋白的安全性和免疫原性行为。

要点

  • 采用免疫信息学方法设计针对克氏锥虫的多表位亚单位疫苗。
  • 基于B细胞和T细胞表位评估免疫原性,预测变应原性和抗原性以确保安全性。
  • 分子对接和分子动力学模拟确认疫苗模型与TLR-2和TLR-4受体复合物的稳定性。

核心结论

  • 设计的疫苗蛋白需要实验验证其安全性和免疫原性行为,未来可能有助于控制克氏锥虫感染。

研究设计与样本

  • 本研究采用免疫信息学方法设计多表位亚单位疫苗,基于免疫原性评估B细胞和T细胞表位,预测变应原性和抗原性以确保疫苗构建体的安全性,理化性质显示最终疫苗模型稳定。

主要发现

  • 分子对接优化了TLR-2和TLR-4受体与疫苗模型配体复合物的相互作用,分子动力学模拟评估能量最小化、RMSD和RMSF图确认免疫细胞上TLR-2和TLR-4受体与疫苗模型配体复合物的稳定性。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chagas disease is a protozoan parasitic disease caused by Trypanosoma cruzi. This injurious disease spread by the circulation of the blood sucking triatomine insects and transmitted to humans. Chagas disease is endemic in Latin America and also known as American trypanosomasis. Currently, 7 million people are infected by T. cruzi infection and about 22,000 death cases were reported per year throughout the Americas. Various immunization approaches against T. cruzi infection have been examined and some of the developed vaccine showed efficacy in animal models but there is no effective and safe vaccines for humans have been developed yet. Since, the drug resistance is increasing day by day because the developed drug (nifurtimox and benznidazole) to control T. cruzi infection, failed to activate a prodrug and still no drug and vaccine have been established. To control the infection of chagas disease, here in this study we use immunoinformatics method to design multi-epitope subunit vaccine against T. cruzi infection. Moreover, on the basis of immunogenicity B and T cell epitopes were evaluated. The allergenicity, antigenicity was predicted to ensure the safety of vaccine constructs whereas, the physiochemical property showing the stable nature of final vaccine model. Further, molecular docking was performed to optimize the interaction between TLR-2 and TLR-4 (receptor) and vaccine model (ligand) complex. Molecular dynamics simulation was performed to evaluate the energy minimization; RMSD and RMSF plot which confirm the stability of TLR-2 and TLR-4 (receptor) present on immune cells and vaccine model (ligand) complex. This study needed the experimental validation for the safety and immunogenic behavior of designed vaccine protein and it may be helpful in future to control T. cruzi infection.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Khatoon N, Ojha R, Mishra A, et al. Examination of antigenic proteins of Trypanosoma cruzi to fabricate an epitope-based subunit vaccine by exploiting epitope mapping mechanism. Vaccine. 2018. PMID: 30217522. doi:10.1016/j.vaccine.2018.09.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。